These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Targeted therapies for cutaneous melanoma. Kee D; McArthur G Hematol Oncol Clin North Am; 2014 Jun; 28(3):491-505. PubMed ID: 24880943 [TBL] [Abstract][Full Text] [Related]
4. Changes in tumor morphology and cyclin-dependent kinase inhibitor expression in metastatic melanoma treated with selective second-generation BRAF inhibitor. Curry JL; Falchook GS; Hwu WJ; Torres-Cabala CA; Duvic M; Tetzlaff MT; Prieto VG Am J Dermatopathol; 2013 Feb; 35(1):125-8. PubMed ID: 22878367 [TBL] [Abstract][Full Text] [Related]
5. [New treatment options for metastatic melanoma]. Tietze JK; Berking C Dtsch Med Wochenschr; 2014 Jul; 139(28-29):1462-7. PubMed ID: 24983194 [No Abstract] [Full Text] [Related]
6. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930 [TBL] [Abstract][Full Text] [Related]
7. Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Lai F; Jiang CC; Farrelly ML; Zhang XD; Hersey P Melanoma Res; 2012 Jun; 22(3):244-51. PubMed ID: 22516966 [TBL] [Abstract][Full Text] [Related]
8. Community experience of vemurafenib for BRAF(V600) melanoma. Hersey P Lancet Oncol; 2014 Apr; 15(4):369-70. PubMed ID: 24582506 [No Abstract] [Full Text] [Related]
9. The new paradigm of systemic therapies for metastatic melanoma. Volpe VO; Klufas DM; Hegde U; Grant-Kels JM J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086 [TBL] [Abstract][Full Text] [Related]
11. The future of melanoma therapy: developing new drugs and improving the use of old ones. Palumbo G; Di Lorenzo G; Ottaviano M; Damiano V Future Oncol; 2016 Nov; 12(22):2531-2534. PubMed ID: 27715206 [No Abstract] [Full Text] [Related]
12. Dabrafenib therapy for advanced melanoma. Trinh VA; Davis JE; Anderson JE; Kim KB Ann Pharmacother; 2014 Apr; 48(4):519-29. PubMed ID: 24259661 [TBL] [Abstract][Full Text] [Related]
13. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505 [TBL] [Abstract][Full Text] [Related]
14. The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy. Akabane H; Sullivan RJ Am J Clin Dermatol; 2016 Feb; 17(1):1-10. PubMed ID: 26518880 [TBL] [Abstract][Full Text] [Related]
15. New RAF kinase inhibitors in cancer therapy. Martin-Liberal J; Larkin J Expert Opin Pharmacother; 2014 Jun; 15(9):1235-45. PubMed ID: 24766074 [TBL] [Abstract][Full Text] [Related]
16. Dabrafenib and its potential for the treatment of metastatic melanoma. Menzies AM; Long GV; Murali R Drug Des Devel Ther; 2012; 6():391-405. PubMed ID: 23251089 [TBL] [Abstract][Full Text] [Related]
17. Strides in melanoma announced: maximizing value comes next. Tuma RS J Natl Cancer Inst; 2011 Jul; 103(13):997-9. PubMed ID: 21693727 [No Abstract] [Full Text] [Related]
18. [Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge]. Capovilla M Ann Pathol; 2013 Dec; 33(6):375-85. PubMed ID: 24331719 [TBL] [Abstract][Full Text] [Related]
19. BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients. Vanhaecke C; Deilhes F; Chanal J; Regnier-Rosencher E; Boitier F; Boulinguez S; Avril MF; Guégan S; Dupin N; Aractingi S; Meyer N; Kramkimel N Br J Dermatol; 2017 Oct; 177(4):e94-e95. PubMed ID: 28129668 [No Abstract] [Full Text] [Related]